Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24966945 | 0.84 | ALDH1A1 (0.47) | CYP1A2CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL24967427 | 0.78 | MAPK1 (0.48) | CYP1A2CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL24435039 | 0.72 | ALDH1A1 (0.40) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL8906122 | 0.71 | CHRM1 (0.39) | CYP1A2CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL6184106 | 0.70 | SCN3A (0.43) | KMT2AKDM4E | |
| SCHEMBL24967416 | 0.70 | GABRA1 (0.39) | CYP1A2CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL8907494 | 0.70 | KMT2A (0.36) | CYP1A2CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL10028355 | 0.69 | KMT2A (0.39) | CYP1A2CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL24966957 | 0.69 | MAPK1 (0.45) | CYP1A2CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL1518200 | 0.69 | RAB9A (0.47) | CYP2C9KMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026724-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUND AND ANESTHETIC EFFECT THEREOF | CHENGDU MFS PHARMA. CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026724-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUND AND ANESTHETIC EFFECT THEREOF | CYP21A2, CYP11B1, CYP11B2 | CYP1A2 42/4885CYP3A4 8/4885CYP2C9 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.